<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lederman, Lynne</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Fukudo, Shin</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Ramosetron Is Effective in Women With IBS-D</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015-08-07 10:43:03</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">14-15</style></pages><abstract><style  face="normal" font="default" size="100%">The serotonin 5-hydroxytryptamine receptor antagonist ramosetron reduces symptoms significantly more than placebo in women with diarrhea-predominant irritable bowel syndrome. Ramosetron is effective in women at half the dose required to reduce symptoms in men and has a manageable side effect profile.</style></abstract><number><style face="normal" font="default" size="100%">14</style></number><volume><style face="normal" font="default" size="100%">15</style></volume></record></records></xml>